Brought to you by 
Knight Therapeutics gets $125mm by selling priority review voucher to Gilead
21 Sep 2020
Executive Summary
Knight Therapeutics Inc., a Paladin Labs spec pharma spin-off, raised $125mm in cash by selling its neglected tropical disease priority review voucher (PRV) to Gilead Sciences Inc. Knight put the PRV up for sale in March 2014.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Knight Therapeutics gets $125mm by selling priority review voucher to Gilead
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice